Exelon
NDC Package 0078-0326-06
Package Information
Exelon is rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Marketed by Novartis Pharmaceuticals Corporation, this product is identified by NDC 0078-0326 and is authorized under FDA application NDA020823.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0078 - Novartis Pharmaceuticals Corporation
- 0078-0326 - Exelon
- 0078-0326-06 - 100 BLISTER PACK in 1 BOX, UNIT-DOSE / 1 CAPSULE in 1 BLISTER PACK (0078-0326-61)
- 0078-0326 - Exelon
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0078-0326). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0078-0326-06 identifies a specific commercial package of 100 blister pack in 1 box, unit-dose / 1 capsule in 1 blister pack (0078-0326-61) of Exelon, labeled by Novartis Pharmaceuticals Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on April 30, 2000. The current certification is valid through February 07, 2020.
What are the primary indications for this medication?
Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.
How is this Novartis Pharmaceuticals Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078032606. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
